BNP/CALL/ELI LILLY & CO/600/0.1/17.01.25 | Market Closed - Boerse Frankfurt Warrants 15:50:26 2024-07-05 EDT | ||
| 31.08 EUR | +3.63% |
|
| Current month | +0.74% | ||
| 1 month | +29.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 31.17 | +3.93% |
| 24-07-04 | 29.99 | +0.74% |
| 24-07-03 | 29.77 | -3.22% |
| 24-07-02 | 30.76 | -1.22% |
| 24-07-01 | 31.14 | +0.65% |
Real-time Boerse Frankfurt Warrants
Last update July 05, 2024 at 03:50 pm
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PZ1XP6 |
| ISIN | DE000PZ1XP60 |
| Date issued | 2023-11-30 |
| Strike | 600 $ |
| Maturity | 2025-01-17 (195 Days) |
| Parity | 10 : 1 |
| Emission price | 8.53 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 31.61 € |
|---|---|
| Lowest since issue | 7.03 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 1.524 |
| Difference Strike | -314.6 $ |
| Difference Strike % | -52.43% |
| Intrinsic value | 29.02 |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.6
USD
Average target price
870.3
USD
Spread / Average Target
-4.84%
- Stock Market
- Warrants
- Warrant
